Gaithersburg, MD, October 22, 2015 --(PR.com
)-- Pregmama LLC announced today achieving the first pregnancy in the company's pilot clinical trial. The baby is due in 2016.
The Veriploid™ therapy is being tested to prevent infertility and miscarriages in order to improve the ability of women in their late thirties and early forties to conceive and achieve healthy, full‐term pregnancies. Women aged 35 and over experience increased infertility, miscarriages, and Down Syndrome pregnancies caused by errors in the process of egg division that cause the egg to have the wrong number of chromosomes. There are no current infertility treatments to improve egg quality.
“Veriploid™ is designed to roll back the clock to enable healthy egg development, meaning an egg with the correct number of chromosomes," said Dr. Lori Bernstein, PhD, inventor of the therapy and Cofounder of Pregmama and Chief Scientific Officer.
According to Barry Datlof, Cofounder and Managing Partner of Pregmama, "Veriploid™ is the first therapy designed to correct chromosome errors so that a woman can have a baby with her own eggs. The therapy does not require IVF or the risk of surgery.”
Pregmama is a female fertility company based in Maryland developing its Veriploid™ therapy to prevent infertility, miscarriages, and birth defects. These conditions cause profound suffering for parents who fail to get pregnant, experience a miscarriage, death of a baby, or rear a disabled child. Pregmama invented Veriploid™ to improve the quality of a woman's eggs and enable healthy babies to be brought into this world.
Barry Datlof, Managing Partner